Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TXN | P10599 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34097 | 0.78 | MEN1 (1.00) | MEN1KMT2AMAPTNPSR1APOBEC3G | |
| SCHEMBL30063472 | 0.78 | MEN1 (1.00) | MEN1KMT2AMAPTNPSR1APOBEC3G | |
| SCHEMBL6863388 | 0.77 | KMT2A (0.54) | MEN1KMT2AMAPTNPSR1APOBEC3G | |
| Hydrochloric Acid SCHEMBL3248165 | 0.76 | MEN1 (0.94) | MEN1KMT2AMAPTNPSR1APOBEC3G | |
| SCHEMBL24596786 | 0.74 | ALDH1A1 (0.41) | MEN1KMT2AMAPTNPSR1APOBEC3G | |
| SCHEMBL16710910 | 0.74 | ALDH1A1 (0.41) | MAPTAPOBEC3GCYP3A4CYP1A2POLB | |
| SCHEMBL9976766 | 0.74 | MEN1 (0.79) | MEN1KMT2AMAPTNPSR1APOBEC3G | |
| SCHEMBL16657271 | 0.71 | MEN1 (0.52) | MEN1KMT2AMAPTNPSR1APOBEC3G | |
| SCHEMBL16602223 | 0.71 | MAPT (0.73) | MEN1KMT2AMAPTNPSR1APOBEC3G | |
| SCHEMBL21084460 | 0.71 | TXN (0.36) | TXN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3503730-B1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3503730-B1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230101227-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-03-30 | — | — | US | disclosed |
| CN-114891053-A | Compositions comprising reversibly modified oligonucleotides and uses thereof | 迪克纳制药公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11390642-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| CN-109890207-B | Compositions comprising reversibly modified oligonucleotides and uses thereof | 迪克纳制药公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3503730-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190177355-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20190177355-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| WO-2018039364-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018039364-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230101227-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | GSS, GSR, RNMT | MEN1 3719/4885KMT2A 3187/4885MAPT 2960/4885 |
| US-11390642-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | GSS, GSR, GSTA2 | MEN1 2361/4885KMT2A 3853/4885MAPT 3574/4885 |
| US-20190177355-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | GSS, GSR, RNMT | MEN1 3719/4885KMT2A 3187/4885MAPT 2960/4885 |
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | GSS, GSR, RNMT | MEN1 3719/4885KMT2A 3187/4885MAPT 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.